Climb Bio, Inc.
Clinical trials sponsored by Climb Bio, Inc., explained in plain language.
-
New drug budoprutug aims to boost platelets in ITP patients
Disease control Recruiting nowThis study tests a new drug called budoprutug in 24 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants must have very low platelet counts despite prior treatments. The main goal is to check safet…
Phase: PHASE1, PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated May 17, 2026 03:25 UTC
-
New drug shows promise for rare kidney disease
Disease control Recruiting nowThis study tests a new drug, budoprutug, in 45 adults with primary membranous nephropathy, a kidney disease where the immune system attacks the kidneys. The goal is to see if the drug is safe and can help reduce protein in the urine, a sign of kidney damage. Participants will rec…
Phase: PHASE2 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New lupus drug candidate enters early human testing
Disease control Recruiting nowThis early-stage study is testing a new drug called budoprutug in 30 adults with active lupus who haven't responded well to other treatments. The main goal is to check if the drug is safe and how the body processes it. Researchers will also look for early signs that it might help…
Phase: PHASE1 • Sponsor: Climb Bio, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug CLYM116 put to the test in healthy volunteers
Knowledge-focused Recruiting nowThis early-stage study is testing a new drug, CLYM116, in 48 healthy adults aged 18 to 60. The main goal is to check if the drug is safe and how the body handles it. Participants will receive either the drug or a placebo as a shot under the skin. This study does not aim to treat …
Phase: PHASE1 • Sponsor: Climb Bio, Inc. • Aim: Knowledge-focused
Last updated May 17, 2026 03:24 UTC